-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ensituximab in Metastatic Pancreatic Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Ensituximab in Metastatic Pancreatic Cancer Drug Details:Ensituximab (NPC-1C, NEO-101, NEO-102) is under development for the treatment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Bevacizumab Biosimilar in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bevacizumab Biosimilar in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bevacizumab Biosimilar in Metastatic Breast Cancer Drug Details: Bevacizumab biosimilar...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bevacizumab Biosimilar in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bevacizumab Biosimilar in Metastatic Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Bevacizumab Biosimilar in Metastatic Colorectal Cancer Drug Details:Bevacizumab biosimilar is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bevacizumab Biosimilar in Metastatic Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bevacizumab Biosimilar in Metastatic Renal Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Bevacizumab Biosimilar in Metastatic Renal Cell Carcinoma Drug Details:Bevacizumab biosimilar...
-
Product Insights
Hip Reconstruction – Enovis Corp – SELEXYS
GlobalData, the industry analysis specialist, has released its latest report: Hip Reconstruction - Enovis Corp - SELEXYS. The selling price or list price of a medical device is driven by numerous factors, such as therapy area and complexity of procedure, level of reimbursement, development costs, the number of competing manufacturers, product life cycle, and whether there have been any recent new technology or product launches. In addition, the final selling pricing of medical devices is also impacted by the discounting...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – darbepoetin alfa
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry darbepoetin alfa Drug Details Darbepoetin alfa (BCD-066) is under development for the treatment of anemia...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – bevacizumab biosimilar
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry bevacizumab biosimilar Drug Details Bevacizumab biosimilar is under development for the treatment of metastatic...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ensituximab
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ensituximab Drug Details Ensituximab (NPC-1C, NEO-101, NEO-102) is under development for the treatment of...
-
Sector Analysis
Outlook for Viral Vector Contract Manufacturing – Gene Therapies, Cell Therapies, and COVID-19 Vaccines
The bio/pharmaceutical industry is experiencing a shortage of viral vectors, a component needed to produce gene therapies and gene-modified cell therapies, as well as certain COVID-19 vaccines that require a viral vector, notably those from AstraZeneca and Johnson & Johnson (J&J). This report reveals that viral vector production is limited by insufficient manufacturing capacity, an inefficient manufacturing process, and the requirement for complex specialist facilities. There are 14 therapies/vaccines that use a viral vector (gene therapies, gene-modified cell therapies, and...
-
Sector Analysis
Contract Manufacturing Service Agreements – Rising Manufacturing Opportunities Driven by Pharmaceutical Pipeline Expansion
This report is a brand new publication covering contract service agreements, across a range of different services and manufacturing scales. The number of contract service agreements secured serves as a primary indicator of a CMO's performance. Contract Manufacturing Service Agreements is critical for establishing an understanding of the overall CMO industry, the range of services provided and the features of some of the largest CMOs participating in the industry.